Skip to content
Call Us Today! 1 (772) 595-9830 info@midwayresearch.com
FacebookTwitterLinkedInInstagram
Midway Research Center Logo Midway Research Center Logo Midway Research Center Logo
  • Home
  • About
  • Clinical Trials
    • Currently Enrolling Studies
    • Active, not recruiting Studies
    • What is a Clinical Trial?
    • Expectations
    • Studies Phases
    • Informed Consent
    • Closed Studies
  • Services
    • HIV
    • STD
    • HPV
    • Lipodystrophy
  • Journal Publications
  • Contact
  • Home
  • About
  • Clinical Trials
    • Currently Enrolling Studies
    • Active, not recruiting Studies
    • What is a Clinical Trial?
    • Expectations
    • Studies Phases
    • Informed Consent
    • Closed Studies
  • Services
    • HIV
    • STD
    • HPV
    • Lipodystrophy
  • Journal Publications
  • Contact

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Biktarvy versus Tivicay and Descovy in Treatment Naive, HIV-1 and Hepatits B CoInfected Adults

Home/A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Biktarvy versus Tivicay and Descovy in Treatment Naive, HIV-1 and Hepatits B CoInfected Adults
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Biktarvy versus Tivicay and Descovy in Treatment Naive, HIV-1 and Hepatits B CoInfected Adultsmidwayadmin2019-04-23T19:32:02+00:00

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Biktarvy versus Tivicay and Descovy in Treatment Naive, HIV-1 and Hepatits B CoInfected Adults

GS-US-380-4458 · Trial ·

Major Inclusion/Exclusion Criteria

  1.  New diagnosis of HIV and Hepatitis B and never taken medications to treat
  2. Can not be co-infected with Hepatitis C 
  3. Can not have decompensated cirrhosis

Read more

© Copyright 2012 -    |   AVADA THEME BY THEMEFUSION   |   ALL RIGHTS RESERVED   |   POWERED BY WORDPRESS
FacebookTwitterLinkedInInstagram